The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma

  1. García-Sanz, R.
  2. González-Fraile, M.I.
  3. Sierra, M.
  4. López, C.
  5. González, M.
  6. San Miguel, J.F.
Revue:
Hematology Journal

ISSN: 1466-4860

Année de publication: 2002

Volumen: 3

Número: 1

Pages: 43-48

Type: Article

DOI: 10.1038/SJ.THJ.6200150 GOOGLE SCHOLAR

Objectifs de Développement Durable

La source de données: Scopus